Nagpur: A patient – Madhusudan Roongta, an industrialist from Chandrapur, was charged with RS3.663 for injection at a pharmacy located in a private hospital while the same medicine from the same company was given to the same patient at the same level of private hospital at the same level .
from RS772.
Foods and Drug Administration (FDA) has confirmed it is a violation and began investigating this case.
Roongta Praddyuman’s son filed a complaint with the FDA on September 15.
“My father was accepted at the Medical Institute of Medical Sciences, Sakkardara, on August 27 for PCNL operations and managed to prostrate 1 gram (Meropenem 1 gram) from Cipla Ltd.
I bought 10 bottles from the pharmacy (Pharmacy Lotus) in the same hospital.
Every vial cost RS3,633.
Because of complications, my father was recognized at Kingsway Hospital on September 3 and recommended the same medicine.
In this hospital, the same drug from the same company was given at RS772, “he said.
“We have to bear the additional costs of Rs30,000.
We are also worried about the poor who cannot afford high prices.
The right demand must be done and justice must be given to all patients,” he said.
Roongta told the Toi it was no less cheating on him.
“The FDA must do a search and see if similar things happen to other medicines.
We need the same medicine in another personal hospital so we know about it.
Otherwise we will never learn about this violation.
In Covid -19 Pandemics, large quantities require various drugs.
Therefore, the FDA must monitor and stop this booty, “he said.
Toi has been on September 15, reports the Commandment of the Supreme Court to the Ministry of Health and Welfare of the Family (Mohfw) to see suggestions from the resident of Arunpal Behal residents for portal development or centralized applications for hospitalization, supply drugs etc.
A pharmacist and filed a petition that accused black marketing and supply of false drugs during the second wave of pandemic.
Assistant Assistant FDA Pushpadas Ballal said, “Official Cipla Ltd said the company reduced prices in February.
The sale of drugs at a long price is not permitted in the revised price case approved.
Usually, the company informs the revision to the dealer, which ultimately continues information to the retailer.
In such cases, the dealer must take back old stock and ensure it is not sold on the market.
In this case, obviously the patient is given the drug for a long time.
Therefore, we are investigating and will take action.
“Lotus’s Pharmacy owner Roshan Chute said,” This is not my fault.
We were not notified by dealers or Cipla Ltd about new price and stock revisions.
Therefore, we continue to sell drugs at the price mentioned on it.
Dealers must take back old stock and replace them with new ones.
“Toi visiting the pharmacy On September 15 and saw long stock available with pharmacies and sold.
Nilesh Chakshekar from Cipla Ltd.
ensures to provide the company version.
Then he did not respond to TOI calls and messages.
The short box Putra Roongta filed a complaint with the FDA * Official FDA said Cipla reduced prices in February, should take old stock, ensure no sale in the market * Medications cannot be sold at a long price after the price revision approved * FDA checks the case * Roongta demands a check if other drugs are also sold like this